12.02SEK+0.17%Mkt Cap: 559.38M SEKP/E: —Last update: 2026-06-01
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassi…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap559.38M SEK
Enterprise Value86.54M SEK
Revenue (TTM)57.47M SEK
Gross Profit57.47M SEK
Net Income (TTM)-183.97M SEK
Revenue/Share1.235 SEK
Last Price12.02 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees21
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0020388577
Valuation
P/E (Trailing)—
P/E (Forward)-2.12
PEG—
EV/EBITDA-0.44
EV/Revenue1.51
P/S9.72
P/B1.51
EPS (TTM)-5.14
EPS (Forward)—
52W Range
11.724% of range19.64
52W High19.64 SEK
52W Low11.72 SEK
Profitability
Gross Margin100.00%
Oper. Margin-444.82%
EBITDA Margin0.00%
Profit Margin-320.12%
ROE-49.80%
ROA-33.66%
Growth
Revenue Growth197.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-74.65M SEK
CapEx (TTM)1.13M SEK
FCF Margin-82.21%
FCF Yield-8.45%
Net Debt-479.36M SEK
Net Debt/EBITDA2.42
Balance Sheet
Debt/Equity0.02
Current Ratio3.92
Quick Ratio3.72
Book Value/Sh7.937 SEK
Cash/Share10.47 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)46.25 SEK
Target Range25.00 SEK – 70.00 SEK
# Analysts4
Ownership
Shares Out.46.54M
Float34.31M
Insiders37.57%
Institutions34.33%
Technical
SMA 5014.26 (-15.7%)
SMA 20016.47 (-27.0%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)196.75K
Avg Vol (10d)39.53K
Technical Indicators
RSI (14)36.6
MACD-0.6251
MACD Signal-0.7920
MACD Hist.+0.1669
BB Upper12.39 SEK
BB Middle12.04 SEK
BB Lower11.70 SEK
BB Width5.70%
ATR (14)0.4824 SEK
Vol Ratio (20d)0.35x